PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10977221

Update on photodynamic therapy.

C D Regillo
View original source ↗Export metadata ↓

Abstract

Photodynamic therapy is a relatively selective form of treatment for choroidal neovascularization. Unlike standard laser photocoagulation, photodynamic therapy can close choroidal neovascularization with minimal or no detectable damage to surrounding tissues. Therefore, it allows the clinician to treat subfoveal choroidal neovascularization without immediately adversely affecting central visual function. Several dyes for photodynamic therapy have been under various stages of formal clinical investigation. There is now mounting evidence that shows that photodynamic therapy with at least one of these dyes can significantly reduce the risk of visual loss in eyes with subfoveal choroidal neovascularization from age-related macular degeneration. This form of treatment promises to have a major, favorable impact on public health in areas of the world in which age-related macular degeneration is common.

Explore related subjects

ChoroidChoroidal NeovascularizationHumansMacular DegenerationOphthalmic SolutionsPhotochemotherapyPhotosensitizing AgentsRetinaTreatment OutcomeJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C D Regillo. 2000. Update on photodynamic therapy.. https://doi.org/10.1097/00055735-200006000-00002

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Theoretical estimation of retinal oxygenation during retinal detachment.

The aim of the present work was to simulate the oxygenation of the whole retina during different degrees of retinal detachment. A differential equation describing the oxygenation of the whole retina, at different degrees of detachment, was set up and solved numerically. The results show that the choroid can supply the outer retina with a fairly large amount of oxygen as long as the detachment height is lower than about 1mm. This study thus supports the view that hyperoxia may well prove to be clinically beneficial.

Choroid↗
PubMed2006

Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions.

Ocular angiogenesis may lead to visual impairment and even irreversible blindness in people of all ages worldwide. Choroidal neovascularization (CNV), a major clinical complication of ocular angiogenesis, is an important cause of vision loss that affects a large number of people. Physiological angiogenesis is tightly controlled by a balance in the expression of angiogenic and anti-angiogenic factors. While the underlying mechanism of CNV is complex, it is attributed to an upset in this balance. The vascular endothelial growth factor (VEGF) is essential in the development of CNV as one of the most potent angiogenic stimulators and vascular permeability factors. Pigment epithelium derived factor (PEDF) is a strong inhibitor of angiogenesis with high neuroprotective effects. VEGF and PEDF both possess multiple biological activities and functions that affect a large variety of tissue cells of the eye and other organs. Inappropriate expression levels are associated with many diseases involving neovascularization. This paper describes the unbalanced expressions of VEGF and PEDF as a cause of CNV. Based on the respective angiogenic and anti-angiogenic properties of VEGF and PEDF, experimental models have been devised to genetically reduce VEGF or enhance PEDF to achieve therapeutic effects. Gene therapy for CNV is promising and is under intensive research.

Choroid↗